Abstract
The ambr250 high-throughput bioreactor platform was adopted to provide a highly-controlled environment for a project investigating genome instability in Chinese hamster ovary (CHO) cells, where genome instability leads to lower protein productivity. Development of the baseline (control) and stressed process conditions highlighted the need to control critical process parameters, including the proportional, integral, and derivative (PID) control loops. Process parameters that are often considered scale-independent, include dissolved oxygen (DO) and pH; however, these parameters were observed to be sensitive to PID settings. For many bioreactors, control loops are cascaded such that the manipulated variables are adjusted concurrently. Conversely, for the ambr250 bioreactor system, the control levels are segmented and implemented sequentially. Consequently, each control level must be tuned independently, as the PID settings are independent by control level. For the CHO cell studies, it was observed that initial PID settings did not resulted in a robust process, which was observed as elevated lactate levels; which was caused by the pH being above the setpoint most of the experiment. After several PID tuning iterations, new PID settings were found that could respond appropriately to routine feed and antifoam additions. Furthermore, these new PID settings resulted in more robust cell growth and increased protein productivity. This work highlights the need to describe PID gains and manipulated variable ranges, as profoundly different outcomes can result from the same feeding protocol. Additionally, improved process models are needed to allow process simulations and tuning. Thus, these tuning experiments support the idea that PID settings should be fully described in bioreactor publications to allow for better reproducibility of results.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Elliott, Kathryn S. 1 ; Skelton, Bradley A. 2 ; Klaubert, Stephanie R. 3 ; Dahodwala, Hussain 4 ; Lee, Kelvin H. 5 1 Clemson University, Department of Bioengineering, Clemson, USA (GRID:grid.26090.3d) (ISNI:0000 0001 0665 0280)
2 Clemson University, Department of Bioengineering, Clemson, USA (GRID:grid.26090.3d) (ISNI:0000 0001 0665 0280); National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Vaccine Research Center, Bethesda, USA (GRID:grid.419681.3) (ISNI:0000 0001 2164 9667)
3 Clemson University, Department of Chemical and Biomolecular Engineering, Clemson, USA (GRID:grid.26090.3d) (ISNI:0000 0001 0665 0280)
4 University of Delaware, Department of Chemical and Biomolecular Engineering, Newark, USA (GRID:grid.33489.35) (ISNI:0000 0001 0454 4791)
5 University of Delaware, Department of Chemical and Biomolecular Engineering, Newark, USA (GRID:grid.33489.35) (ISNI:0000 0001 0454 4791); University of Delaware, National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), Newark, USA (GRID:grid.33489.35) (ISNI:0000 0001 0454 4791)




